Autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen class II alleles in chronic fatigue syndrome: are they associated with age at onset and specific symptoms? — CFSMEATLAS
Autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen class II alleles in chronic fatigue syndrome: are they associated with age at onset and specific symptoms?
Ortega-Hernandez, Oscar-Danilo, Cuccia, Mariaclara, Bozzini, Sara et al. · Annals of the New York Academy of Sciences · 2009 · DOI
Quick Summary
This study looked at whether certain genetic traits and immune markers in the blood are linked to when ME/CFS develops and what symptoms people experience. Researchers tested 81 ME/CFS patients for specific genes related to serotonin (a brain chemical), immune system genes, and antibodies. They found that different genetic patterns were associated with developing ME/CFS at different ages and with certain symptoms like joint pain and fever, but not muscle pain.
Why It Matters
This study suggests that ME/CFS is genetically heterogeneous, similar to other autoimmune diseases, meaning different people may develop the illness through different biological mechanisms. Understanding these genetic associations could eventually help predict disease onset timing and symptom profiles, potentially improving early detection and personalized treatment approaches.
Observed Findings
Mean age at CFS onset was 33.5 ± 12.5 years across 81 patients.
HTR2A AA genotype and HLA-DRB1*03 allele were associated with CFS onset during the third decade of life.
HTR2A AG genotype was protective against depressive symptoms, while female sex and ≥1 copy of serotonin A allele increased arthralgia risk.
HLA-DRB1*11 allele was associated with episodes of unexplained fever.
No genetic or serological features correlated with myalgia, and no antibodies significantly associated with age at onset or other symptoms.
Inferred Conclusions
Different genetic features in the serotonin pathway and HLA system are associated with distinct patterns of CFS onset age and specific symptoms.
ME/CFS demonstrates genetic heterogeneity similar to other autoimmune diseases, suggesting multiple biological pathways may lead to disease development.
Autoantibodies tested in this study do not appear to be significant biomarkers for CFS onset timing or symptom presentation.
Genetic architecture may help explain phenotypic diversity in ME/CFS presentation across different age groups.
Remaining Questions
What is the biological mechanism linking these genetic variants to different ages of ME/CFS onset?
What This Study Does Not Prove
This study does not prove that these genetic variants cause ME/CFS—it only shows associations observed at one point in time. The cross-sectional design cannot establish causality or temporal relationships, and the relatively small sample size means these associations need validation in larger, prospective studies before clinical application. Autoantibody findings were negative, so the role of antibodies in ME/CFS remains unclear.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →